Elan Corporation Plc reported an operating profit of $36.2 million for the first quarter of 2010 after an operating loss a year earlier, driven by strong sales of its multiple sclerosis drug, Tysabri (natalizumab), and a reduction in expenses. ---Subscribe to MedNous to access this article--- Company News
